{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T11:44:27Z","timestamp":1778327067220,"version":"3.51.4"},"reference-count":24,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"management of DEVA Holding A.S., Istanbul\/Turkey"},{"DOI":"10.13039\/501100004410","name":"Scientific and Technological Research Council of Turkey","doi-asserted-by":"publisher","award":["3150314"],"award-info":[{"award-number":["3150314"]}],"id":[{"id":"10.13039\/501100004410","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"published-print":{"date-parts":[[2020,5]]},"DOI":"10.1016\/j.jpba.2020.113145","type":"journal-article","created":{"date-parts":[[2020,2,5]],"date-time":"2020-02-05T11:30:37Z","timestamp":1580902237000},"page":"113145","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Synthesis and characterization of oxitropium bromide related substances and novel stability indicating HPLC methods"],"prefix":"10.1016","volume":"183","author":[{"given":"Esen","family":"Bellur Atici","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00c7a\u011fan","family":"A\u011fta\u015f","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y\u00fccel","family":"Yazar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nurten","family":"R\u0131dvano\u011flu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpba.2020.113145_bib0005","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1159\/000194065","article-title":"Oxitropium bromide, a new anticholinergic drug, in a dose-response and placebo comparison in obstructive airway diseases","volume":"38","author":"Flohr","year":"1979","journal-title":"Respiration"},{"key":"10.1016\/j.jpba.2020.113145_bib0010","first-page":"57","article-title":"Oxitropium bromide, ipratropium bromide and fenoterol in exercise-induced asthma","volume":"43","author":"Larsson","year":"1982","journal-title":"Respiration"},{"key":"10.1016\/j.jpba.2020.113145_bib0015","first-page":"106","article-title":"A comparison of oxitropium bromide and ipratropium bromide in asthma","volume":"65","author":"Peel","year":"1984","journal-title":"Eur. J. Respir. Dis."},{"key":"10.1016\/j.jpba.2020.113145_bib0020","doi-asserted-by":"crossref","first-page":"33","DOI":"10.2147\/copd.2007.2.1.33","article-title":"The development of anticholinergics in the management of COPD","volume":"2","author":"Scullion","year":"2007","journal-title":"Int. J. COPD"},{"key":"10.1016\/j.jpba.2020.113145_bib0025","doi-asserted-by":"crossref","first-page":"3448","DOI":"10.1021\/ja01595a051","article-title":"Antispasmodics. VIII. Scopolamine derivatives","volume":"78","author":"Moffett","year":"1956","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.jpba.2020.113145_bib0030","unstructured":"K. Zeile, R. Banholzer, G. Walther, W. Schulz, H. Wick, N-Substitution products of norscopolamine and quarternary salts thereof, US Patent 3,472,861 (1969)."},{"key":"10.1016\/j.jpba.2020.113145_bib0035","series-title":"Oxitropium Bromide 01\/2008:2170, European Pharmacopoeia 10.0","first-page":"3450","year":"2008"},{"key":"10.1016\/j.jpba.2020.113145_bib0040","doi-asserted-by":"crossref","first-page":"14191","DOI":"10.1021\/ja105508b","article-title":"The thermosalient phenomenon. \u201cJumping crystals\u201d and crystal chemistry of the anticholinergic agent oxitropium bromide","volume":"132","author":"Skoko","year":"2010","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.jpba.2020.113145_bib0045","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1016\/S0731-7085(98)00083-1","article-title":"Validated capillary electrophoresis method for the determination of atropine and scopolamine derivatives in pharmaceutical formulations","volume":"17","author":"Cherkaoui","year":"1998","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2020.113145_bib0050","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/S0731-7085(98)00223-4","article-title":"Capillary electrophoresis for the analysis of tropane alkaloids: pharmaceutical and phytochemical applications","volume":"18","author":"Mateus","year":"1998","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2020.113145_bib0055","article-title":"Guidance for industry Q3A (R2), Impurities in new drug substances","year":"2008","journal-title":"International Conference on Harmonisation"},{"key":"10.1016\/j.jpba.2020.113145_bib0060","article-title":"Guidance for industry Q3B (R2), Impurities in new drug products","year":"2006","journal-title":"International Conference on Harmonisation"},{"key":"10.1016\/j.jpba.2020.113145_bib0065","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1016\/j.talanta.2005.04.026","article-title":"Analysis of scopolamine and its eighteen metabolites in rat urine by liquid chromatography-tandem mass spectrometry","volume":"67","author":"Chen","year":"2005","journal-title":"Talanta"},{"key":"10.1016\/j.jpba.2020.113145_bib0070","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/j.jpba.2006.07.039","article-title":"Impurity profiling of atropine sulfate by microemulsion electrokinetic chromatography","volume":"44","author":"Bitar","year":"2007","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2020.113145_bib0075","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.jpba.2009.11.026","article-title":"Development and validation of a stability indicating RP-HPLC method for the simultaneous determination of related substances of albuterol sulfate and ipratropium bromide in nasal solution","volume":"52","author":"Kasawar","year":"2010","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2020.113145_bib0080","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.jpha.2015.02.001","article-title":"Identification, synthesis and characterization of process related impurities of benidipine hydrochloride, stress-testing \/ stability studies and HPLC\/UPLC method validations","volume":"5","author":"Bellur Atici","year":"2015","journal-title":"J. Pharm. Anal."},{"key":"10.1016\/j.jpba.2020.113145_bib0085","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.jpha.2015.04.002","article-title":"Identification, synthesis and characterization of process related desfluoro impurity of ezetimibe and HPLC method validations","volume":"5","author":"Bellur Atici","year":"2015","journal-title":"J. Pharm. Anal."},{"key":"10.1016\/j.jpba.2020.113145_bib0090","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jpba.2016.12.032","article-title":"Development and validation of stability indicating HPLC methods for related substances and assay analyses of amoxicillin and potassium clavulanate mixtures","volume":"136","author":"Bellur Atici","year":"2017","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2020.113145_bib0095","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.jpba.2018.12.008","article-title":"Isolation, identification, characterization, synthesis and quality control strategy of new process-related impurities in ambrisentan","volume":"165","author":"Feng","year":"2019","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2020.113145_bib0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2019.112808","article-title":"A novel HPLC method for analysis of atosiban and its five related substances in atosiban acetate injection","volume":"177","author":"Li","year":"2020","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2020.113145_bib0105","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1080\/00397910601039119","article-title":"Synthesis of ipratropium bromide-related compounds","volume":"37","author":"Tsyskovskaia","year":"2007","journal-title":"Synth. Commun."},{"key":"10.1016\/j.jpba.2020.113145_bib0110","article-title":"Validation of analytical procedures","author":"I.C.H.Q.2 (R1)","year":"2005","journal-title":"International Conference on Harmonisation"},{"key":"10.1016\/j.jpba.2020.113145_bib0115","article-title":"Guidance for Industry Q1A (R2), Stability testing of new drug substances and products","year":"2003","journal-title":"International Conference on Harmonisation"},{"key":"10.1016\/j.jpba.2020.113145_bib0120","article-title":"Stability testing: Photostability testing of new drug substances and products Q1B","year":"1996","journal-title":"International Conference on Harmonisation"}],"container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708519331619?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708519331619?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T09:00:20Z","timestamp":1760000420000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0731708519331619"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5]]},"references-count":24,"alternative-id":["S0731708519331619"],"URL":"https:\/\/doi.org\/10.1016\/j.jpba.2020.113145","relation":{},"ISSN":["0731-7085"],"issn-type":[{"value":"0731-7085","type":"print"}],"subject":[],"published":{"date-parts":[[2020,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Synthesis and characterization of oxitropium bromide related substances and novel stability indicating HPLC methods","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical and Biomedical Analysis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpba.2020.113145","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"113145"}}